Cost-Utility Analysis of IEV Drug Regimen Versus ESHAP Drug Regimen for the Patients With Relapsed and Refractory Hodgkin and Non-Hodgkin’s Lymphoma in Iran
Iranian Journal of Cancer Prevention
doi 10.17795/ijcp-4061
Full Text
Open PDFAbstract
Available in full text
Date
October 27, 2015
Authors
Publisher
Kowsar Medical Institute